Specialist and smaller company funds dominate the top 10 Standard & Poor's (S&P) unit trust and Oeic...
Specialist and smaller company funds dominate the top 10 Standard & Poor's (S&P) unit trust and Oeic rankings over three years, with CF Bio-Tech coming out top. The £18.1m CF Bio-Tech portfolio does not feature S&P ratings or stars, yet its three-year returns place it higher than all other unit trusts or Oeics. In the three years to 1 November 2001 a £1,000 investment measured on an offer to bid basis with net income reinvested would have grown to £3,518.14. Framlington Health is the other specialist fund to feature in the rankings, with the same £1,000 being worth £2,369.50 after thre...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
